董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jill M. Jene | 女 | Director | 52 | 未披露 | 未持股 | 2026-01-01 |
| Spyros Papapetropoulos | 男 | Lead Independent Director and Chairman of the Board | 52 | 未披露 | 未持股 | 2026-01-01 |
| Mahesh V. Patel | 男 | President, Chief Executive Officer and Director | 69 | 52.06万美元 | 未持股 | 2026-01-01 |
| John W. Higuchi | 男 | Director | 58 | 4.60万美元 | 未持股 | 2026-01-01 |
| Richard Dana Ono | 男 | Director | 71 | 5.60万美元 | 未持股 | 2026-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nachiappan Chidambaram | 男 | Senior Vice President, Research and Development | 57 | 26.91万美元 | 未持股 | 2026-01-01 |
| Krista Fogarty | 女 | Principal Accounting Officer and Corporate Controller | 58 | 未披露 | 未持股 | 2026-01-01 |
| Mahesh V. Patel | 男 | President, Chief Executive Officer and Director | 69 | 52.06万美元 | 未持股 | 2026-01-01 |
董事简历
中英对照 | 中文 | 英文- Jill M. Jene
-
Jill M. Jene已经积累了超过60亿美元的已完成交易的交易单，她目前是生物制药咨询公司Jene Advisors的创始人和负责人，她自2021年11月以来一直担任该职位。Jene博士从2020年8月起担任Adamas的副总裁兼企业发展、战略、投资组合规划和联盟管理负责人，直到该公司于2021年11月被出售给Supernus。在加入Adamas之前，Jene博士于2018年5月至2020年8月担任PDL业务发展副总裁，这是一家上市的生物技术公司，她负责执行交易，为股东实现价值最大化。在加入PDL之前，Jene博士于2017年5月至2018年5月在TwoXAR领导业务发展，在那里她领导了交易制定，最终完成了6个新的合作伙伴关系，并获得了软银和A16z的A轮融资。在加入twoXAR之前，Jene博士于2006年4月至2017年5月在Depomed（现为Assertio）工作，在那里她领导了超过36笔交易，包括许可和并购交易，包括收购4个商业特许经营权。在她职业生涯的早期，她曾在百特国际、3M公司（制药部门现为Valeant的一部分）和Cell Genesys（被Biosante收购）担任越来越重要的职务。Jene博士获得了布拉德利大学的学士学位、西北大学的化学硕士和博士学位，以及德保罗大学的战略管理工商管理硕士学位。
Jill M. Jene,has amassed a deal sheet of over $6 billion of closed transactions and she is currently the Founder and Principal of Jene Advisors, a biopharmaceutical advisory firm, a position she has held since November 2021. Dr. Jene was the Vice President and Head of Corporate Development, Strategy, Portfolio Planning and Alliance Management at Adamas from August 2020, until the company was sold to Supernus in November of 2021. Before joining Adamas, Dr. Jene was Vice President of Business Development for PDL from May 2018 to August 2020, a publicly traded biotechnology company where she was responsible for executing deal-making to maximize value for shareholders. Before PDL, Dr. Jene led Business Development at twoXAR from May 2017 to May 2018, where she led deal-making, resulting in closing 6 new partnerships and securing Series A funding from Softbank and A16z. Prior to twoXAR, Dr. Jene was at Depomed (now Assertio) from April 2006 to May 2017, where she led over 36 transactions including licensing and M&A deals including acquiring 4 commercial franchises. Earlier in her career, she held positions of increasing responsibility at Baxter International, the 3M Company (Pharmaceutical Division now part of Valeant) and Cell Genesys (acquired by Biosante). Dr. Jene earned a B.S. from Bradley University, a M.S. and Ph.D. in Chemistry from Northwestern University, and an M.B.A. in strategic management from DePaul University. - Jill M. Jene已经积累了超过60亿美元的已完成交易的交易单，她目前是生物制药咨询公司Jene Advisors的创始人和负责人，她自2021年11月以来一直担任该职位。Jene博士从2020年8月起担任Adamas的副总裁兼企业发展、战略、投资组合规划和联盟管理负责人，直到该公司于2021年11月被出售给Supernus。在加入Adamas之前，Jene博士于2018年5月至2020年8月担任PDL业务发展副总裁，这是一家上市的生物技术公司，她负责执行交易，为股东实现价值最大化。在加入PDL之前，Jene博士于2017年5月至2018年5月在TwoXAR领导业务发展，在那里她领导了交易制定，最终完成了6个新的合作伙伴关系，并获得了软银和A16z的A轮融资。在加入twoXAR之前，Jene博士于2006年4月至2017年5月在Depomed（现为Assertio）工作，在那里她领导了超过36笔交易，包括许可和并购交易，包括收购4个商业特许经营权。在她职业生涯的早期，她曾在百特国际、3M公司（制药部门现为Valeant的一部分）和Cell Genesys（被Biosante收购）担任越来越重要的职务。Jene博士获得了布拉德利大学的学士学位、西北大学的化学硕士和博士学位，以及德保罗大学的战略管理工商管理硕士学位。
- Jill M. Jene,has amassed a deal sheet of over $6 billion of closed transactions and she is currently the Founder and Principal of Jene Advisors, a biopharmaceutical advisory firm, a position she has held since November 2021. Dr. Jene was the Vice President and Head of Corporate Development, Strategy, Portfolio Planning and Alliance Management at Adamas from August 2020, until the company was sold to Supernus in November of 2021. Before joining Adamas, Dr. Jene was Vice President of Business Development for PDL from May 2018 to August 2020, a publicly traded biotechnology company where she was responsible for executing deal-making to maximize value for shareholders. Before PDL, Dr. Jene led Business Development at twoXAR from May 2017 to May 2018, where she led deal-making, resulting in closing 6 new partnerships and securing Series A funding from Softbank and A16z. Prior to twoXAR, Dr. Jene was at Depomed (now Assertio) from April 2006 to May 2017, where she led over 36 transactions including licensing and M&A deals including acquiring 4 commercial franchises. Earlier in her career, she held positions of increasing responsibility at Baxter International, the 3M Company (Pharmaceutical Division now part of Valeant) and Cell Genesys (acquired by Biosante). Dr. Jene earned a B.S. from Bradley University, a M.S. and Ph.D. in Chemistry from Northwestern University, and an M.B.A. in strategic management from DePaul University.
- Spyros Papapetropoulos
-
Spyros Papapetropoulos，历任Neuphoria Therapeutics Inc.（前身为Bionomics Ltd）（纳斯达克股票代码：NEUP）总裁、首席执行官和董事会董事等职务。在加入Neurphoria之前，Papapetropoulos博士曾担任Vigil Neuroscience的首席医疗官，他自2020年9月起担任该职位，负责监督所有的临床开发和医疗职能。在加入Vigil之前，Papapetropoulos博士于2019年11月至2020年9月在阿卡迪亚公司担任高级副总裁兼开发主管（CDO），于2019年3月至2020年10月在SwanBio Therapeutics担任首席执行官，并于2017年6月至2019年3月在Cavion担任研发主管兼首席医疗官。在加入Cavion之前，他曾在Biogen Inc.、Allergan PLC、辉瑞公司和梯瓦制药公司担任高级/高管职务。Papapetropoulos博士监督了广泛的生物制药开发项目，包括小分子、生物制剂和基因治疗，从而在全球范围内成功提交监管申请和推出新产品。他担任麻省总医院的顾问，并参与了导致帕金森病遗传形式表征的研究，并开发了与临床研究环境中神经运动功能量化相关的方法学。Papapetropoulos博士发表了170多篇同行评审文章，并撰写了多个书籍章节和专利。Papapetropoulos博士在希腊获得Patras大学医学院的医学博士和博士学位。
Spyros Papapetropoulos,has served as President, Chief Executive Officer and as a Board Director of Neuphoria Therapeutics Inc. (formerly Bionomics Ltd) (NASDAQ: NEUP). Prior to Neurphoria, Dr. Papapetropoulos served as Chief Medical Officer at Vigil Neuroscience, a position he has held since September 2020, where he oversaw all the clinical development and medical functions. Prior to Vigil, Dr. Papapetropoulos served as SVP, Head of Development (CDO) at Acadia Pharmaceuticals Inc. from November 2019 to September 2020, CEO at SwanBio Therapeutics from March 2019 to October 2020, and Head of Research & Development and Chief Medical Officer at Cavion from June 2017 to March 2019. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Dr. Papapetropoulos has overseen a broad spectrum of biopharmaceutical development programs including small molecules, biologics, and gene therapy leading to successful regulatory filings and new product launches worldwide. He holds appointments as Consultant with Massachusetts General Hospital and has been involved in research that led to the characterization of genetic forms of Parkinson's disease and development of methodologies relating to the quantification of neuromotor function in clinical research settings. Dr. Papapetropoulos has published more than 170 peer reviewed articles and authored several book chapters and patents. Dr. Papapetropoulos received his M.D. and Ph.D. in Greece from the University of Patras, School of Medicine. - Spyros Papapetropoulos，历任Neuphoria Therapeutics Inc.（前身为Bionomics Ltd）（纳斯达克股票代码：NEUP）总裁、首席执行官和董事会董事等职务。在加入Neurphoria之前，Papapetropoulos博士曾担任Vigil Neuroscience的首席医疗官，他自2020年9月起担任该职位，负责监督所有的临床开发和医疗职能。在加入Vigil之前，Papapetropoulos博士于2019年11月至2020年9月在阿卡迪亚公司担任高级副总裁兼开发主管（CDO），于2019年3月至2020年10月在SwanBio Therapeutics担任首席执行官，并于2017年6月至2019年3月在Cavion担任研发主管兼首席医疗官。在加入Cavion之前，他曾在Biogen Inc.、Allergan PLC、辉瑞公司和梯瓦制药公司担任高级/高管职务。Papapetropoulos博士监督了广泛的生物制药开发项目，包括小分子、生物制剂和基因治疗，从而在全球范围内成功提交监管申请和推出新产品。他担任麻省总医院的顾问，并参与了导致帕金森病遗传形式表征的研究，并开发了与临床研究环境中神经运动功能量化相关的方法学。Papapetropoulos博士发表了170多篇同行评审文章，并撰写了多个书籍章节和专利。Papapetropoulos博士在希腊获得Patras大学医学院的医学博士和博士学位。
- Spyros Papapetropoulos,has served as President, Chief Executive Officer and as a Board Director of Neuphoria Therapeutics Inc. (formerly Bionomics Ltd) (NASDAQ: NEUP). Prior to Neurphoria, Dr. Papapetropoulos served as Chief Medical Officer at Vigil Neuroscience, a position he has held since September 2020, where he oversaw all the clinical development and medical functions. Prior to Vigil, Dr. Papapetropoulos served as SVP, Head of Development (CDO) at Acadia Pharmaceuticals Inc. from November 2019 to September 2020, CEO at SwanBio Therapeutics from March 2019 to October 2020, and Head of Research & Development and Chief Medical Officer at Cavion from June 2017 to March 2019. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Dr. Papapetropoulos has overseen a broad spectrum of biopharmaceutical development programs including small molecules, biologics, and gene therapy leading to successful regulatory filings and new product launches worldwide. He holds appointments as Consultant with Massachusetts General Hospital and has been involved in research that led to the characterization of genetic forms of Parkinson's disease and development of methodologies relating to the quantification of neuromotor function in clinical research settings. Dr. Papapetropoulos has published more than 170 peer reviewed articles and authored several book chapters and patents. Dr. Papapetropoulos received his M.D. and Ph.D. in Greece from the University of Patras, School of Medicine.
- Mahesh V. Patel
-
Mahesh V. Patel，博士。自1997年，他担任我们的总裁兼首席执行长，并作为我们董事会的成员，他目前担任我们董事会的主席。Patel博士拥有超过25年的战略规划，技术评估和开发，在药物发现支持，药物输送和产品线扩展这一领域的技术管理和产品研究及开发。在1997年共建Lipocine之前，他在Pharmacia和Upjohn领导药物输送研究和开发。 Patel博士在Karnataka University in India获得药剂学学士，在the University of Cincinnati获得物理药学硕士学位，并在the University of Utah获得药剂学博士学位。
Mahesh V. Patel,has more than 30 years of experience in strategic planning, technology assessment/development, technical management and product research and development in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, he led drug delivery research and development at Pharmacia and Upjohn. Dr. Patel received a B.Pharm from Karnataka University in India, a M.S. in Physical Pharmacy at the University of Cincinnati and a Ph.D. in Pharmaceutics from the University of Utah. - Mahesh V. Patel，博士。自1997年，他担任我们的总裁兼首席执行长，并作为我们董事会的成员，他目前担任我们董事会的主席。Patel博士拥有超过25年的战略规划，技术评估和开发，在药物发现支持，药物输送和产品线扩展这一领域的技术管理和产品研究及开发。在1997年共建Lipocine之前，他在Pharmacia和Upjohn领导药物输送研究和开发。 Patel博士在Karnataka University in India获得药剂学学士，在the University of Cincinnati获得物理药学硕士学位，并在the University of Utah获得药剂学博士学位。
- Mahesh V. Patel,has more than 30 years of experience in strategic planning, technology assessment/development, technical management and product research and development in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, he led drug delivery research and development at Pharmacia and Upjohn. Dr. Patel received a B.Pharm from Karnataka University in India, a M.S. in Physical Pharmacy at the University of Cincinnati and a Ph.D. in Pharmaceutics from the University of Utah.
- John W. Higuchi
-
John W. Higuchi，工商管理硕士。自2003年，他担任我们董事会的成员。自2003年，Higuchi先生担任Aciont Inc.，一家眼科药物治疗公司的总裁和首席执行长。1997年至2003年，Higuchi担任业务发展的副总裁和公司出纳员。Higuchi先生也在American Chemical Society工作过。Higuchi先生在Hope College获得化学学生学位，并在The George Washington University获得信息系统学硕士和工商管理硕士。
John W. Higuchi,served as Chief Executive Officer of Aciont Inc., an ocular therapeutics company in Utah from 2003 to 2022. Mr. Higuchi also is a co-founder and serves on the Board of Directors of Spriaso, LLC, a specialty pharmaceutical company in Utah. From 1997 to 2003, Mr. Higuchi served as Lipocine Inc. Vice President of Business Development and Corporate Treasurer. Mr. Higuchi received a B.S. in Chemistry from Hope College and an M.B.A. and M.S. in Information Systems from The George Washington University. - John W. Higuchi，工商管理硕士。自2003年，他担任我们董事会的成员。自2003年，Higuchi先生担任Aciont Inc.，一家眼科药物治疗公司的总裁和首席执行长。1997年至2003年，Higuchi担任业务发展的副总裁和公司出纳员。Higuchi先生也在American Chemical Society工作过。Higuchi先生在Hope College获得化学学生学位，并在The George Washington University获得信息系统学硕士和工商管理硕士。
- John W. Higuchi,served as Chief Executive Officer of Aciont Inc., an ocular therapeutics company in Utah from 2003 to 2022. Mr. Higuchi also is a co-founder and serves on the Board of Directors of Spriaso, LLC, a specialty pharmaceutical company in Utah. From 1997 to 2003, Mr. Higuchi served as Lipocine Inc. Vice President of Business Development and Corporate Treasurer. Mr. Higuchi received a B.S. in Chemistry from Hope College and an M.B.A. and M.S. in Information Systems from The George Washington University.
- Richard Dana Ono
-
Richard Dana Ono，博士，在2014年1月。在他的整个职业生涯中，他一直为多个早期生命科学公司从事战略规划、产品管理、技术收购、商业开发，并且参与了这个产业的许多关键进展。Ono博士在美国建立了几家生物技术公司，包括生物技术公司 IntraImmune Therapies, Inc.，他将这个公司出售给了Abgenix, Inc.现在Amgen，与几个位于波士顿地区的成功的早期生物技术公司。现在，他是在2000年起就工作的VIMAC Ventures LLC中的风险合伙人。
Richard Dana Ono,has been an executive-in-residence to several universities in the United States advising their licensing offices in spin-outs and new company formation from promising technologies. Throughout his career, he has been engaged in strategic planning, product management, technology acquisition, and commercial development of life science start-ups and has been involved in a number of pioneering milestones in biotechnology. Dr. Ono has founded several biotech companies in the U.S. Dr. Ono is a founding director of the Massachusetts Biotechnology Council, Inc. (MassBio) and served on the Board of Trustees of the Marine Biological Laboratory in Woods Hole, Massachusetts. He is a Fellow of the Linnean Society of London and a National Member of the Explorers Club. Dr. Ono received his A.B. in Earth & Planetary Sciences from The Johns Hopkins University and his A.M. and Ph. D. in Biology from Harvard University, where he also completed a program in business administration. - Richard Dana Ono，博士，在2014年1月。在他的整个职业生涯中，他一直为多个早期生命科学公司从事战略规划、产品管理、技术收购、商业开发，并且参与了这个产业的许多关键进展。Ono博士在美国建立了几家生物技术公司，包括生物技术公司 IntraImmune Therapies, Inc.，他将这个公司出售给了Abgenix, Inc.现在Amgen，与几个位于波士顿地区的成功的早期生物技术公司。现在，他是在2000年起就工作的VIMAC Ventures LLC中的风险合伙人。
- Richard Dana Ono,has been an executive-in-residence to several universities in the United States advising their licensing offices in spin-outs and new company formation from promising technologies. Throughout his career, he has been engaged in strategic planning, product management, technology acquisition, and commercial development of life science start-ups and has been involved in a number of pioneering milestones in biotechnology. Dr. Ono has founded several biotech companies in the U.S. Dr. Ono is a founding director of the Massachusetts Biotechnology Council, Inc. (MassBio) and served on the Board of Trustees of the Marine Biological Laboratory in Woods Hole, Massachusetts. He is a Fellow of the Linnean Society of London and a National Member of the Explorers Club. Dr. Ono received his A.B. in Earth & Planetary Sciences from The Johns Hopkins University and his A.M. and Ph. D. in Biology from Harvard University, where he also completed a program in business administration.
高管简历
中英对照 | 中文 | 英文- Nachiappan Chidambaram
Nachiappan Chidambaram博士自2014年7月以来一直担任我们的Vice President产品开发，并在制药和生物技术领域拥有超过18年的产品开发经验。在晋升为产品开发Vice President之前，奇丹巴拉姆博士曾于2007年至2014年担任多个产品开发领导职务，包括产品开发副主任。在2007年加入Lipocine之前，Chidambaram博士从2000年到2007年担任Banner Pharmacaps的集团负责人。他于2000年获得the University of Connecticut的药剂学博士学位。
Nachiappan Chidambaram,served in various product development leadership roles with the Company including Associate Director, Product Development, from 2007 to 2014. Prior to joining Lipocine in 2007, Dr. Chidambaram served as the Group Leader at Banner Pharmacaps from 2000 to 2007. He received his Ph.D. in Pharmaceutics from the University of Connecticut in 2000.- Nachiappan Chidambaram博士自2014年7月以来一直担任我们的Vice President产品开发，并在制药和生物技术领域拥有超过18年的产品开发经验。在晋升为产品开发Vice President之前，奇丹巴拉姆博士曾于2007年至2014年担任多个产品开发领导职务，包括产品开发副主任。在2007年加入Lipocine之前，Chidambaram博士从2000年到2007年担任Banner Pharmacaps的集团负责人。他于2000年获得the University of Connecticut的药剂学博士学位。
- Nachiappan Chidambaram,served in various product development leadership roles with the Company including Associate Director, Product Development, from 2007 to 2014. Prior to joining Lipocine in 2007, Dr. Chidambaram served as the Group Leader at Banner Pharmacaps from 2000 to 2007. He received his Ph.D. in Pharmaceutics from the University of Connecticut in 2000.
- Krista Fogarty
Krista Fogarty，2017年至2018年在ABA疗法服务提供商Alternative Behavior Strategies担任首席财务官,2016年至2017年在药物发现和药物开发公司Navigen担任财务总监和业务运营副总裁。在此之前，她曾于2013年至2016年在个人基因组学和生物技术公司Lineagen担任财务副总裁。Fogarty女士此前还曾在生物技术公司NPS生物制药担任公司财务总监。Fogarty女士获得了犹他州立大学会计学学士学位，还获得了犹他州立大学的MACC。
Krista Fogarty,served as Chief Financial Officer at Alternative Behavior Strategies, a provider of ABA therapy services from 2017 to 2018, and as Controller and Associate VP Business Operations at Navigen, a pharmaceutical discovery and drug development company, from 2016 to 2017. Prior to that she served as VP Finance at Lineagen, a personal genomics and biotechnology company from 2013 to 2016. Ms. Fogarty also previously served as Corporate Controller at NPS Pharmaceuticals, a biotechnology company. Ms. Fogarty received a B.S. in Accounting from Utah State University and also received a MAcc from Utah State University.- Krista Fogarty，2017年至2018年在ABA疗法服务提供商Alternative Behavior Strategies担任首席财务官,2016年至2017年在药物发现和药物开发公司Navigen担任财务总监和业务运营副总裁。在此之前，她曾于2013年至2016年在个人基因组学和生物技术公司Lineagen担任财务副总裁。Fogarty女士此前还曾在生物技术公司NPS生物制药担任公司财务总监。Fogarty女士获得了犹他州立大学会计学学士学位，还获得了犹他州立大学的MACC。
- Krista Fogarty,served as Chief Financial Officer at Alternative Behavior Strategies, a provider of ABA therapy services from 2017 to 2018, and as Controller and Associate VP Business Operations at Navigen, a pharmaceutical discovery and drug development company, from 2016 to 2017. Prior to that she served as VP Finance at Lineagen, a personal genomics and biotechnology company from 2013 to 2016. Ms. Fogarty also previously served as Corporate Controller at NPS Pharmaceuticals, a biotechnology company. Ms. Fogarty received a B.S. in Accounting from Utah State University and also received a MAcc from Utah State University.
- Mahesh V. Patel
Mahesh V. Patel，博士。自1997年，他担任我们的总裁兼首席执行长，并作为我们董事会的成员，他目前担任我们董事会的主席。Patel博士拥有超过25年的战略规划，技术评估和开发，在药物发现支持，药物输送和产品线扩展这一领域的技术管理和产品研究及开发。在1997年共建Lipocine之前，他在Pharmacia和Upjohn领导药物输送研究和开发。 Patel博士在Karnataka University in India获得药剂学学士，在the University of Cincinnati获得物理药学硕士学位，并在the University of Utah获得药剂学博士学位。
Mahesh V. Patel,has more than 30 years of experience in strategic planning, technology assessment/development, technical management and product research and development in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, he led drug delivery research and development at Pharmacia and Upjohn. Dr. Patel received a B.Pharm from Karnataka University in India, a M.S. in Physical Pharmacy at the University of Cincinnati and a Ph.D. in Pharmaceutics from the University of Utah.- Mahesh V. Patel，博士。自1997年，他担任我们的总裁兼首席执行长，并作为我们董事会的成员，他目前担任我们董事会的主席。Patel博士拥有超过25年的战略规划，技术评估和开发，在药物发现支持，药物输送和产品线扩展这一领域的技术管理和产品研究及开发。在1997年共建Lipocine之前，他在Pharmacia和Upjohn领导药物输送研究和开发。 Patel博士在Karnataka University in India获得药剂学学士，在the University of Cincinnati获得物理药学硕士学位，并在the University of Utah获得药剂学博士学位。
- Mahesh V. Patel,has more than 30 years of experience in strategic planning, technology assessment/development, technical management and product research and development in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, he led drug delivery research and development at Pharmacia and Upjohn. Dr. Patel received a B.Pharm from Karnataka University in India, a M.S. in Physical Pharmacy at the University of Cincinnati and a Ph.D. in Pharmaceutics from the University of Utah.